709 related articles for article (PubMed ID: 31200861)
1. Monitoring and deciphering protein degradation pathways inside cells.
Daniels DL; Riching KM; Urh M
Drug Discov Today Technol; 2019 Apr; 31():61-68. PubMed ID: 31200861
[TBL] [Abstract][Full Text] [Related]
2. Quantitative Live-Cell Kinetic Degradation and Mechanistic Profiling of PROTAC Mode of Action.
Riching KM; Mahan S; Corona CR; McDougall M; Vasta JD; Robers MB; Urh M; Daniels DL
ACS Chem Biol; 2018 Sep; 13(9):2758-2770. PubMed ID: 30137962
[TBL] [Abstract][Full Text] [Related]
3. Kinetic Detection of E3:PROTAC:Target Ternary Complexes Using NanoBRET Technology in Live Cells.
Mahan SD; Riching KM; Urh M; Daniels DL
Methods Mol Biol; 2021; 2365():151-171. PubMed ID: 34432243
[TBL] [Abstract][Full Text] [Related]
4. Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets.
Xiong Y; Zhong Y; Yim H; Yang X; Park KS; Xie L; Poulikakos PI; Han X; Xiong Y; Chen X; Liu J; Jin J
J Am Chem Soc; 2022 Dec; 144(49):22622-22632. PubMed ID: 36448571
[TBL] [Abstract][Full Text] [Related]
5. Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.
Bondeson DP; Smith BE; Burslem GM; Buhimschi AD; Hines J; Jaime-Figueroa S; Wang J; Hamman BD; Ishchenko A; Crews CM
Cell Chem Biol; 2018 Jan; 25(1):78-87.e5. PubMed ID: 29129718
[TBL] [Abstract][Full Text] [Related]
6. Modeling the CRL4A ligase complex to predict target protein ubiquitination induced by cereblon-recruiting PROTACs.
Bai N; Riching KM; Makaju A; Wu H; Acker TM; Ou SC; Zhang Y; Shen X; Bulloch DN; Rui H; Gibson BW; Daniels DL; Urh M; Rock BM; Humphreys SC
J Biol Chem; 2022 Apr; 298(4):101653. PubMed ID: 35101445
[TBL] [Abstract][Full Text] [Related]
7. PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery.
Gu S; Cui D; Chen X; Xiong X; Zhao Y
Bioessays; 2018 Apr; 40(4):e1700247. PubMed ID: 29473971
[TBL] [Abstract][Full Text] [Related]
8. Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy.
Li X; Song Y
J Hematol Oncol; 2020 May; 13(1):50. PubMed ID: 32404196
[TBL] [Abstract][Full Text] [Related]
9. Targeted protein degradation by PROTACs.
Neklesa TK; Winkler JD; Crews CM
Pharmacol Ther; 2017 Jun; 174():138-144. PubMed ID: 28223226
[TBL] [Abstract][Full Text] [Related]
10. Delineating the role of cooperativity in the design of potent PROTACs for BTK.
Zorba A; Nguyen C; Xu Y; Starr J; Borzilleri K; Smith J; Zhu H; Farley KA; Ding W; Schiemer J; Feng X; Chang JS; Uccello DP; Young JA; Garcia-Irrizary CN; Czabaniuk L; Schuff B; Oliver R; Montgomery J; Hayward MM; Coe J; Chen J; Niosi M; Luthra S; Shah JC; El-Kattan A; Qiu X; West GM; Noe MC; Shanmugasundaram V; Gilbert AM; Brown MF; Calabrese MF
Proc Natl Acad Sci U S A; 2018 Jul; 115(31):E7285-E7292. PubMed ID: 30012605
[TBL] [Abstract][Full Text] [Related]
11. PROTAC-induced Protein Functional Dynamics in Targeted Protein Degradation.
Wu KY; Hung TI; Chang CA
bioRxiv; 2024 May; ():. PubMed ID: 38746111
[TBL] [Abstract][Full Text] [Related]
12. Tracking the PROTAC degradation pathway in living cells highlights the importance of ternary complex measurement for PROTAC optimization.
Schwalm MP; Krämer A; Dölle A; Weckesser J; Yu X; Jin J; Saxena K; Knapp S
Cell Chem Biol; 2023 Jul; 30(7):753-765.e8. PubMed ID: 37354907
[TBL] [Abstract][Full Text] [Related]
13. Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL.
Lai AC; Toure M; Hellerschmied D; Salami J; Jaime-Figueroa S; Ko E; Hines J; Crews CM
Angew Chem Int Ed Engl; 2016 Jan; 55(2):807-10. PubMed ID: 26593377
[TBL] [Abstract][Full Text] [Related]
14. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
[TBL] [Abstract][Full Text] [Related]
15. Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase.
Smith BE; Wang SL; Jaime-Figueroa S; Harbin A; Wang J; Hamman BD; Crews CM
Nat Commun; 2019 Jan; 10(1):131. PubMed ID: 30631068
[TBL] [Abstract][Full Text] [Related]
16. Optimization of PROTAC Ternary Complex Using DNA Encoded Library Approach.
Chen Q; Liu C; Wang W; Meng X; Cheng X; Li X; Cai L; Luo L; He X; Qu H; Luo J; Wei H; Gao S; Liu G; Wan J; Israel DI; Li J; Dou D
ACS Chem Biol; 2023 Jan; 18(1):25-33. PubMed ID: 36606710
[TBL] [Abstract][Full Text] [Related]
17. E3 ligase ligand chemistries: from building blocks to protein degraders.
Sosič I; Bricelj A; Steinebach C
Chem Soc Rev; 2022 May; 51(9):3487-3534. PubMed ID: 35393989
[TBL] [Abstract][Full Text] [Related]
18. PROTACs to address the challenges facing small molecule inhibitors.
Martín-Acosta P; Xiao X
Eur J Med Chem; 2021 Jan; 210():112993. PubMed ID: 33189436
[TBL] [Abstract][Full Text] [Related]
19. Proteolysis targeting chimeras (PROTACs) in cancer therapy.
Ocaña A; Pandiella A
J Exp Clin Cancer Res; 2020 Sep; 39(1):189. PubMed ID: 32933565
[TBL] [Abstract][Full Text] [Related]
20. Assays and technologies for developing proteolysis targeting chimera degraders.
Liu X; Zhang X; Lv D; Yuan Y; Zheng G; Zhou D
Future Med Chem; 2020 Jun; 12(12):1155-1179. PubMed ID: 32431173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
